Jerome Hass: Why I Shorted Valeant Near Its Peak

The transcript discusses the financial concerns surrounding a company's acquisition of Salix Pharmaceuticals, which increased its debt to EBITDAR ratio to six times. This raised red flags about the company's ability to take on more debt, affecting its share price and investment strategies. Concerns about leadership, particularly regarding excessive management remuneration, are highlighted. The discussion concludes with a strategic outlook, suggesting a cautious approach due to the crowded short position in the market.

What concerns were raised regarding the acquisition of Salix Pharmaceuticals?

How did the debt to EBITDAR ratio change after the acquisition mentioned?

What red flags were identified in the leadership of the company?

What factors contributed to the decision to exit the short position?

What was the speaker's perspective on the company's future and their position?